Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL (2024) Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, et al. Journal article Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study (2023) Ruppert R, Junginger T, Kube R, Strassburg J, Lewin A, Baral J, Maurer CA, et al. Journal article Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival (2023) Lopes Cardozo JM, Andrulis IL, Bojesen SE, Dörk T, Eccles DM, Fasching P, Hooning MJ, et al. Journal article Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas (2023) Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kühn J, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? (2022) Hope TA, Pavel ME, Bergsland EK Journal article, Review article Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma (2022) Grimm MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, et al. Journal article Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. (2022) Hecht M, Eckstein M, Kallies A, Klautke G, Illmer T, von der Grün J, Laban S, et al. Conference contribution High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma (2022) Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, Van Den Berg H, et al. Journal article Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. (2022) Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, et al. Journal article